Introduction {#H1-1-ZOI190377}
============

Randomized clinical trials designed with a noninferiority hypothesis test whether the experimental treatment is worse than the standard of care by a given margin called the *noninferiority margin*.^[@zoi190377r1]^ Noninferiority trials are useful to test interventions that aim at providing compensatory benefits without necessarily compromising efficacy. If the new drug or strategy reduces cost or adverse effects or improves the ease of administration, patients may reasonably accept the possibility of slight reductions in efficacy.

However, there are numerous concerns associated with defining, designing, conducting, reporting, and interpreting noninferiority trials,^[@zoi190377r1],[@zoi190377r2]^ including in oncology.^[@zoi190377r3]^ For example, how much of a possible reduction in efficacy is reasonable? How noninferiority limits are defined may raise ethical issues related to the sufficiency of patient informed consent.^[@zoi190377r4]^ In some cases, noninferiority designs have been useful. For example, the standard of care for the use of zoledronic acid for preventing skeletal-related events in patients with cancer and bone metastases used to be an injection every month. Noninferiority trials have now established that the frequency could safely be reduced to once every 3 months without compromising efficacy outcomes.^[@zoi190377r5],[@zoi190377r6]^

Noninferiority trials have been applied sparingly to oncology drugs because patients with cancer are unlikely to accept even the possibility of reduced efficacy of their oncology drugs. However, in a 2018 case, a noninferiority trial served as the pivotal trial for US Food and Drug Administration approval of a new cancer drug, even though the new drug did not necessarily provide any benefits in terms of cost, ease of administration, or toxic effects.^[@zoi190377r7]^ Previous studies have shown that industry-funded trials were more likely to use a noninferiority design than nonindustry-sponsored trials.^[@zoi190377r8]^

In cancer treatment, noninferiority trials with overall survival (OS) outcomes are most critical from a clinical and regulatory point of view because it would be unwise to use a new therapy based on its noninferiority regarding response rates or progression-free survival without knowing the effects on OS, as the drug might very well have more substantially inferior outcomes on survival. Similarly, patients are most concerned with compromise in survival when the results from noninferiority trials are translated in clinics.

To understand the characteristics of noninferiority trials used in evaluating cancer drugs, we sought to systematically review the use of the noninferiority hypothesis in randomized clinical trials in the field of oncology. In this systematic review and pooled analysis, we investigated the basis or reasoning for using noninferiority designs, the funding of these trials, and efficacy outcomes.

Methods {#H1-2-ZOI190377}
=======

The objectives of this study were as follows: (1) to study the characteristics of randomized cancer drug trials that use noninferiority design, including the success rate and justification for using noninferiority designs, (2) to study whether the success in claiming noninferiority or the lack of justification for using noninferiority design was associated with the source of funding, and (3) to study the overall association of the drug being tested with patients' survival. This study was conducted in accordance with the modification of Preferred Reporting Items for Systematic Reviews and Meta-analyses ([PRISMA](http://www.equator-network.org/reporting-guidelines/prisma/)) reporting guideline for meta-epidemiological studies.^[@zoi190377r9]^

Study Identification {#H2-1-ZOI190377}
--------------------

We conducted a systematic search of the PubMed database in March 2018 without date restrictions, supplemented with a search of the Google Scholar database. To identify published trials in cancer that used a noninferiority design, we used the search terms *neoplasms* or *cancer* or *tumo\** or *malignan\** or *oncology* AND *non inferior\**or *non-inferior\**or *noninferior\** and limited our search to findings published in English. After title and abstract screening by 2 of us (B.G. and F.A.T.) acting independently, the full texts of potentially relevant studies were downloaded and reviewed for the following exclusion criteria: (1) not a randomized design; (2) trials in pediatric populations; (3) trials of surgery or radiotherapy only in all treatment arms (trials comparing a drug in 1 arm and surgery or radiotherapy in other arms were eligible); (4) trials of decision support, diagnostic modalities, or supportive care; (5) trials assessing behavioral interventions, genetic counseling, screening, or diagnostic modalities; (6) trials assessing only pharmacokinetics; and (7) post hoc analyses. For this study, we limited our analysis to trials with a primary or a coprimary end point of OS for 2 reasons. First, the most important concern for patients making treatment decisions based on noninferiority trials is the potential for compromise in survival, rather than compromise in surrogate measures. Second, we planned to conduct a pooled analysis, and it would not be possible to pool survival with other surrogate measures across the trials.

Data Extraction {#H2-2-ZOI190377}
---------------

Data were independently extracted from published reports by 2 of us (F.A.T. and E.H.J) and verified by a third author (B.G.), with discrepancies resolved through consensus of all authors. We collected year of publication, treatment setting, primary end point, sample size, blinding (ie, double blind or open label), funding (ie, public, industry, or mixed public and industry), and the authors' listed criteria for using a noninferiority design.

We judged whether the noninferiority design was justified for each trial. Noninferiority was considered justified if the intervention being tested provided at least 1 of the following benefits to patients: (1) less cost; (2) decreased frequency of administration; (3) increased ease of administration, such as noninjectable (eg, oral) vs injectable formulation; or (4) improved quality of life.

We also extracted information on the outcome of the trial in terms of whether noninferiority was achieved. A trial was considered successful if it achieved noninferiority based on its own criteria. For trials that achieved noninferiority, we checked if the intervention also proved superiority based on 95% CIs and whether the publication concluded superiority. For quality-of-life outcomes, we considered quality of life to be improved if the summary was statistically better; we did not examine each domain of the assessment tool separately. Finally, information on the hazard ratio (HR) and 95% CI for OS were extracted from the published reports for pooled analysis. If a CI different from a 95% CI was reported, we recalculated the CI to a 95% CI.

Statistical Analysis {#H2-3-ZOI190377}
--------------------

The associations of the justification for using the noninferiority design and success in achieving noninferiority with the funding source were assessed using Fisher exact tests. The overall association of the trial drugs on OS was assessed by pooling the HRs across the trials using a random-effects meta-analysis to account for heterogeneity. Heterogeneity among studies was assessed using the Cochrane *Q* statistic (assumption of homogeneity was considered invalid for values of *P* \< .10) and quantified using an *I*^2^ test. Subgroup analyses were prespecified and included funding, blinding, and success. All statistical analyses were conducted using Stata version 15 (StataCorp), and a 2-sided *P* \< .05 was considered statistically significant.

Results {#H1-3-ZOI190377}
=======

Among 128 randomized noninferiority trials in oncology in adults identified through our search, 74 (58%) were drug trials. Of those, 23 (31%) enrolled 21 437 patients, used OS as the primary or coprimary end point, and were therefore included in our analysis ([Figure 1](#zoi190377f1){ref-type="fig"} and [Table 1](#zoi190377t1){ref-type="table"}).^[@zoi190377r10],[@zoi190377r11],[@zoi190377r12],[@zoi190377r13],[@zoi190377r14],[@zoi190377r15],[@zoi190377r16],[@zoi190377r17],[@zoi190377r18],[@zoi190377r19],[@zoi190377r20],[@zoi190377r21],[@zoi190377r22],[@zoi190377r23],[@zoi190377r24],[@zoi190377r25],[@zoi190377r26],[@zoi190377r27],[@zoi190377r28],[@zoi190377r29],[@zoi190377r30],[@zoi190377r31],[@zoi190377r32]^ None of these trials were blinded. Approximately half (12 \[52%\]) had industry funding, 5 (22%) were publicly funded, and 6 (26%) had mixed funding.

![Flow Diagram for the Selection of Studies](jamanetwopen-2-e199570-g001){#zoi190377f1}

###### Justifications for Noninferiority Trials of Cancer Drugs in Oncology With Overall Survival Endpoint

  Source                                                                           Total Participants, No.   Cancer Type   Patients, No.   QoL Results   Justification of Noninferiority Design                
  -------------------------------------------------------------------------------- ------------------------- ------------- --------------- ------------- ----------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Adams et al,^[@zoi190377r10]^ 2011                                               2445                      Colorectal    815             815           Better                                                Justified: intermittent vs continuous oxaliplatin
  Boku et al,^[@zoi190377r11]^ 2009                                                468                       Gastric       234             234           Not assessed                                          Justified: oral S-1 vs IV 5-FU; S-1 less expensive
  Crook et al,^[@zoi190377r12]^ 2012                                               1386                      Prostate      690             696           Better                                                Justified: intermittent vs continuous androgen deprivation therapy
  daSilva et al,^[@zoi190377r13]^ 2014                                             918                       Prostate      462             456           Not statistically different                           Justified: intermittent vs continuous androgen deprivation therapy
  Ferry et al,^[@zoi190377r14]^ 2017                                               909                       NSCLC         453             456           Not different; statistical comparison not provided    Justified: carboplatin vs cisplatin
  Fink et al,^[@zoi190377r15]^ 2012                                                795                       SCLC          346             334           Not assessed                                          Not justified: topotecan-cisplatin vs cisplatin-etoposide
  Hofheinz et al,^[@zoi190377r16]^ 2012                                            392                       Colorectal    195             197           Not assessed                                          Justified: oral capecitabine vs IV 5-FU
  Hussain et al,^[@zoi190377r17]^ 2013                                             1535                      Prostate      770             765           Slightly better but summary statistic not available   Justified: intermittent vs continuous hormone therapy
  Kehoe et al,^[@zoi190377r18]^ 2015                                               500                       Ovarian       274             276           Not statistically different                           Justified: avoiding surgery
  Kim et al,^[@zoi190377r19]^ 2008                                                 1433                      NSCLC         723             710           Better                                                Justified: oral gefitinib vs IV docetaxel
  Kim et al,^[@zoi190377r20]^ 2009                                                 491                       Colorectal    246             245           Not reported                                          Not justified: FOLFOX vs irinotecan
  Kitagawa et al,^[@zoi190377r21]^ 2015                                            253                       Cervical      126             127           Better                                                Justified: carboplatin vs cisplatin; less hospitalization time
  Kubota et al,^[@zoi190377r22]^ 2015                                              608                       NSCLC         301             295           Better                                                Justified: oral S-1 vs IV docetaxel in combination with platinum
  Kudo et al,^[@zoi190377r23]^ 2018                                                1492                      Liver         476             475           Not statistically different                           Not justified: lenvatinib vs sorafenib; lenvatinib costs more than sorafenib and offers no other benefits
  Lang et al,^[@zoi190377r24]^ 2013                                                564                       Breast        279             285           Not statistically different                           Not justified: bevacizumab plus capecitabine vs bevacizumab plus paclitaxel; capecitabine and paclitaxel are both established as first-line agents; the control arm of bevacizumab plus paclitaxel is now withdrawn by the FDA
  Okamoto et al,^[@zoi190377r25]^ 2010                                             564                       NSCLC         282             281           Not statistically different                           Justified: oral S-1 vs IV paclitaxel in combination with carboplatin
  Popov et al,^[@zoi190377r26]^ 2008                                               1921                      Colorectal    952             969           Not assessed                                          Not justified: IV ralitrexed vs IV 5-FU
  Price et al,^[@zoi190377r27]^ 2016                                               1010                      Colorectal    596             594           Not assessed                                          Not justified: panitumumab vs cetuximab
  Satouchi et al,^[@zoi190377r28]^ 2014                                            284                       SCLC          142             142           Not statistically different                           Not justified: amrubicin-platinum vs irinotecan-platinum
  Scagliotti et al,^[@zoi190377r29]^ 2008                                          1725                      NSCLC         862             863           Not assessed                                          Not justified: cisplatin-pemetrexed vs cisplatin-gemcitabine; pemetrexed offered a better profile for some adverse effects but was much more expensive than gemcitabine
  Shitara et al,^[@zoi190377r30]^ 2017[^a^](#zoi190377t1n1){ref-type="table-fn"}   741                       Gastric       246 and 247     248           Statistical comparison not provided                   Not justified: abraxane 3 times per week vs abraxane weekly vs paclitaxel weekly; abraxane costs more than 50-fold what paclitaxel costs; premedication not necessary with abraxane
  Takashima et al,^[@zoi190377r31]^ 2016                                           618                       Breast        309             309           Better                                                Justified: oral S-1 vs IV taxane
  Uesaka et al,^[@zoi190377r32]^ 2016                                              385                       Pancreas      192             193           Better                                                Justified: oral S-1 vs IV gemcitabine

Abbreviations: FDA, US Food and Drug Administration; FOLFOX, 5-fluorouracil plus leucovorin plus oxaliplatin; 5-FU, 5-fluorouracil; IV, intravenous; NSCLC, non--small cell lung cancer; QoL, quality of life; SCLC, small cell lung cancer.

The trial by Shitara et al^[@zoi190377r30]^ had 3 arms.

Noninferiority was defined in terms of the upper limit of the CI of the HR for OS in 20 (87%) trials. Most trials used 95% CIs,^[@zoi190377r11],[@zoi190377r12],[@zoi190377r13],[@zoi190377r14],[@zoi190377r20],[@zoi190377r22],[@zoi190377r23],[@zoi190377r24],[@zoi190377r25],[@zoi190377r26],[@zoi190377r28],[@zoi190377r29],[@zoi190377r30],[@zoi190377r31],[@zoi190377r32]^ but some used 90% CIs,^[@zoi190377r17],[@zoi190377r18],[@zoi190377r21]^ 96% CIs,^[@zoi190377r19]^ and 80% CIs^[@zoi190377r10]^ (Table 2). A 2012 trial^[@zoi190377r16]^ defined noninferiority in terms of difference in 5-year OS rates, a 2016 trial as retaining at least 50% of the OS effects of the control arm,^[@zoi190377r27]^ and a 2012 trial in terms of the lower limit of the 95% CI for median OS greater than median minus 10% of the overall survival of the control arm^[@zoi190377r15]^ ([Table 2](#zoi190377t2){ref-type="table"}).

###### Outcomes of Noninferiority Trials of Cancer Drugs in Oncology With OS End Point

  Source                                                                            Cancer Type   Funding    Noninferiority Criteria for Hazard Ratio                                                    Success                       OS, HR (95% CI)
  --------------------------------------------------------------------------------- ------------- ---------- ------------------------------------------------------------------------------------------- ----------------------------- --------------------------------------------------
  Adams et al,^[@zoi190377r10]^ 2011[^a^](#zoi190377t2n1){ref-type="table-fn"}      Colorectal    Mixed      1.162[^b^](#zoi190377t2n2){ref-type="table-fn"}                                             No                            1.08 (1.01-1.17)
  Boku et al,^[@zoi190377r11]^ 2009                                                 Gastric       Mixed      1.16[^c^](#zoi190377t2n3){ref-type="table-fn"}                                              Yes                           0.83 (0.68-1.01)
  Crook et al,^[@zoi190377r12]^ 2012                                                Prostate      Public     1.25[^c^](#zoi190377t2n3){ref-type="table-fn"}                                              Yes                           1.02 (0.86-1.21)
  daSilva et al,^[@zoi190377r13]^ 2014                                              Prostate      Public     1.21[^c^](#zoi190377t2n3){ref-type="table-fn"}                                              Yes                           0.90 (0.76-1.07)
  Ferry et al,^[@zoi190377r14]^ 2017                                                NSCLC         Mixed      1.2[^c^](#zoi190377t2n3){ref-type="table-fn"}                                               Yes                           0.93 (0.83-1.04)
  Fink et al,^[@zoi190377r15]^ 2012                                                 SCLC          Industry   Lower limit of 95% CI of median OS should be \>10% less than the median OS of control arm   Yes                           0.93 (0.79-1.10)
  Hofheinz et al,^[@zoi190377r16]^ 2012                                             Colorectal    Industry   5-y OS rate difference 12.5%                                                                Yes                           0.67 (0.44-1.00)
  Hussain et al,^[@zoi190377r17]^ 2013[^a^](#zoi190377t2n1){ref-type="table-fn"}    Prostate      Public     1.2[^d^](#zoi190377t2n4){ref-type="table-fn"}                                               No                            1.10 (0.99-1.23)
  Kehoe et al,^[@zoi190377r18]^ 2015[^a^](#zoi190377t2n1){ref-type="table-fn"}      Ovarian       Public     1.18[^d^](#zoi190377t2n4){ref-type="table-fn"}                                              Yes                           0.87 (0.72-1.05)
  Kim et al,^[@zoi190377r19]^ 2008[^a^](#zoi190377t2n1){ref-type="table-fn"}        NSCLC         Industry   1.154[^e^](#zoi190377t2n5){ref-type="table-fn"}                                             Yes                           1.02 (0.91-1.15)
  Kim et al,^[@zoi190377r20]^ 2009                                                  Colorectal    Industry   1.33[^c^](#zoi190377t2n3){ref-type="table-fn"}                                              Yes                           0.92 (0.80-1.10)
  Kitagawa et al,^[@zoi190377r21]^ 2015[^a^](#zoi190377t2n1){ref-type="table-fn"}   Cervical      Public     1.29[^d^](#zoi190377t2n4){ref-type="table-fn"}                                              Yes                           0.99 (0.79-1.25)
  Kubota et al,^[@zoi190377r22]^ 2015                                               NSCLC         Industry   1.322[^c^](#zoi190377t2n3){ref-type="table-fn"}                                             Yes                           1.01 (0.84-1.23)
  Kudo et al,^[@zoi190377r23]^ 2018                                                 Liver         Industry   1.08[^c^](#zoi190377t2n3){ref-type="table-fn"}                                              Yes                           0.92 (0.79-1.06)
  Lang et al,^[@zoi190377r24]^ 2013                                                 Breast        Mixed      1.33[^c^](#zoi190377t2n3){ref-type="table-fn"}                                              No                            1.06 (0.80-1.40)
  Okamoto et al,^[@zoi190377r25]^ 2010[^a^](#zoi190377t2n1){ref-type="table-fn"}    NSCLC         Industry   1.33[^c^](#zoi190377t2n3){ref-type="table-fn"}                                              Yes                           0.93 (0.69-1.17)
  Popov et al,^[@zoi190377r26]^ 2008                                                Colorectal    Industry   1.25[^c^](#zoi190377t2n3){ref-type="table-fn"}                                              No                            1.01 (0.84-1.23)
  Price et al,^[@zoi190377r27]^ 2016                                                Colorectal    Industry   ≥50% Retention of OS effects of control                                                     Yes                           0.94 (0.82-1.07)
  Satouchi et al,^[@zoi190377r28]^ 2014                                             SCLC          Industry   1.31[^c^](#zoi190377t2n3){ref-type="table-fn"}                                              No                            1.43 (1.10-1.85)
  Scagliotti et al,^[@zoi190377r29]^ 2008                                           NSCLC         Industry   1.176[^c^](#zoi190377t2n3){ref-type="table-fn"}                                             Yes                           0.94 (0.84-1.05)
  Shitara et al,^[@zoi190377r30]^ 2017[^f^](#zoi190377t2n6){ref-type="table-fn"}    Gastric       Industry   1.25[^c^](#zoi190377t2n3){ref-type="table-fn"}                                              Yes for arm A; no for arm B   Arm A, 0.97 (0.76-1.23); arm B, 1.06 (0.87-1.31)
  Takashima et al,^[@zoi190377r31]^ 2016                                            Breast        Mixed      1.333[^c^](#zoi190377t2n3){ref-type="table-fn"}                                             Yes                           1.05 (0.86-1.27)
  Uesaka et al,^[@zoi190377r32]^ 2016                                               Pancreas      Mixed      1.25[^c^](#zoi190377t2n3){ref-type="table-fn"}                                              Yes                           0.57 (0.44-0.72)

Abbreviations: HR, hazard ratio; NSCLC, non--small cell lung cancer; OS, overall survival; SCLC, small cell lung cancer.

Reported a CI different from a 95% CI, which was recalculated in the Table to 95% CIs.

Noninferiority criteria defined by upper limit of 80% CI for HR.

Noninferiority criteria defined by upper limit of 95% CI for HR.

Noninferiority criteria defined by upper limit of 90% CI for HR.

Noninferiority criteria defined by upper limit of 96% CI for HR.

The trial by Shitara et al^[@zoi190377r30]^ had 3 arms.

The upper limit of the CI for the HR for OS in the 20 trials that used that measure as their criteria for noninferiority ranged from 1.08 to 1.33. Of these, 14 trials (70%)^[@zoi190377r12],[@zoi190377r13],[@zoi190377r14],[@zoi190377r17],[@zoi190377r20],[@zoi190377r21],[@zoi190377r22],[@zoi190377r24],[@zoi190377r25],[@zoi190377r28],[@zoi190377r30],[@zoi190377r31],[@zoi190377r32]^ had a limit of 1.2 or more, meaning that up to a 20% increase in mortality risk was considered noninferior (ie, acceptable). A 2017 trial^[@zoi190377r30]^ had 3 arms comparing 2 different regimens in noninferiority design against the control.^[@zoi190377r30]^ Quality of life was improved in 8 trials (35%),^[@zoi190377r10],[@zoi190377r12],[@zoi190377r17],[@zoi190377r19],[@zoi190377r21],[@zoi190377r22],[@zoi190377r31],[@zoi190377r32]^ not improved in another 8 (35%),^[@zoi190377r13],[@zoi190377r14],[@zoi190377r18],[@zoi190377r23],[@zoi190377r24],[@zoi190377r25],[@zoi190377r28],[@zoi190377r30]^ and not assessed or assessed but not reported in the remaining 7 (30%) ([Table 1](#zoi190377t1){ref-type="table"}).^[@zoi190377r11],[@zoi190377r15],[@zoi190377r16],[@zoi190377r20],[@zoi190377r26],[@zoi190377r27],[@zoi190377r29]^

Justification for Noninferiority {#H2-4-ZOI190377}
--------------------------------

Overall, 14 trials (61%) met our criteria for justifying the noninferiority design ([Table 1](#zoi190377t1){ref-type="table"}).^[@zoi190377r10],[@zoi190377r11],[@zoi190377r12],[@zoi190377r13],[@zoi190377r14],[@zoi190377r16],[@zoi190377r17],[@zoi190377r18],[@zoi190377r19],[@zoi190377r21],[@zoi190377r22],[@zoi190377r25],[@zoi190377r31],[@zoi190377r32]^ A new oral drug vs injectable standard was the most common justification (7 trials)^[@zoi190377r11],[@zoi190377r16],[@zoi190377r19],[@zoi190377r22],[@zoi190377r25],[@zoi190377r31],[@zoi190377r32]^ for using the noninferiority design, followed by intermittent vs continuous therapies (4 trials).^[@zoi190377r10],[@zoi190377r12],[@zoi190377r13],[@zoi190377r17]^ Other justifications included avoiding surgery with chemotherapy^[@zoi190377r18]^ or using carboplatin instead of cisplatin.^[@zoi190377r14],[@zoi190377r21]^

Among the 9 noninferiority trials (39%) that did not meet our justification criteria, comparisons were made between oral-oral or intravenous-intravenous drugs, usually of the same class. Most trials^[@zoi190377r15],[@zoi190377r20],[@zoi190377r23],[@zoi190377r26],[@zoi190377r27],[@zoi190377r28],[@zoi190377r29],[@zoi190377r30]^ (8 \[89%\]) that did not meet any justification for noninferiority were industry funded, while 1 trial^[@zoi190377r24]^ had mixed funding. All publicly funded noninferiority trials met the criteria for justification. Lack of justification was associated with funding source (*P* = .02, assessed using the Fisher exact test).

Success in Establishing Noninferiority {#H2-5-ZOI190377}
--------------------------------------

A total of 18 trials (78%) established noninferiority for the intervention drug ([Table 2](#zoi190377t2){ref-type="table"}).^[@zoi190377r11],[@zoi190377r12],[@zoi190377r13],[@zoi190377r14],[@zoi190377r15],[@zoi190377r16],[@zoi190377r18],[@zoi190377r19],[@zoi190377r20],[@zoi190377r21],[@zoi190377r22],[@zoi190377r23],[@zoi190377r25],[@zoi190377r27],[@zoi190377r29],[@zoi190377r30],[@zoi190377r31],[@zoi190377r32]^ One trial^[@zoi190377r32]^ proved superiority. Of the 12 industry-funded trials, 10 established noninferiority for the drug being tested.^[@zoi190377r15],[@zoi190377r16],[@zoi190377r19],[@zoi190377r20],[@zoi190377r22],[@zoi190377r23],[@zoi190377r25],[@zoi190377r27],[@zoi190377r29],[@zoi190377r30]^ Success in achieving noninferiority was not associated with funding (*P* = .80, assessed using the Fisher exact test).

Association With OS {#H2-6-ZOI190377}
-------------------

The HR was more than 1 in 10 trials (41%),^[@zoi190377r10],[@zoi190377r12],[@zoi190377r17],[@zoi190377r19],[@zoi190377r22],[@zoi190377r24],[@zoi190377r26],[@zoi190377r28],[@zoi190377r30],[@zoi190377r31]^ but was significant in only 1 trial^[@zoi190377r28]^ ([Table 2](#zoi190377t2){ref-type="table"}). When the HRs across trials were pooled using random-effects meta-analysis, there was no beneficial or detrimental association with patient survival (pooled HR, 0.97; 95% CI, 0.92-1.02); the heterogeneity among the trials was substantial as trials across different tumor types were pooled (*I*^2^ = 53.8%, *P* = .001) ([Figure 2](#zoi190377f2){ref-type="fig"}). This analysis was repeated using comparisons for each cohort of the trial by Shitara et al^[@zoi190377r30]^ (the trial with 3 arms) independently and results did not change. On subgroup analysis, there was no difference between industry-funded trials vs mixed or publicly funded trials as well as no difference between trials in which noninferiority design was justified vs not justified.

![Pooled Analysis of Hazard Ratios (HRs) of Overall Survival\
Weights are determined from random-effects analysis. The size of each box represents the weight by random-effects method of the contribution of each study to the weight of the sample in meta-analysis. The vertical dashed line indicates the point of summary HR, and the diamond indicates the 95% CI for the summary HR. Hazard ratio values less than 1 reflect protective effects of treatment, and HR values greater than 1 reflect detrimental effects of treatment on survival.](jamanetwopen-2-e199570-g002){#zoi190377f2}

Discussion {#H1-4-ZOI190377}
==========

In systematically searching for noninferiority trials of cancer drugs, we found that only 31% used OS as the primary end point. Among these trials, the criteria to define noninferiority varied from 1.08 to 1.33 for the upper limit of the CI of the HR for death. Ease of administration (oral formulation vs injectable control drugs) was the most common justification for the noninferiority design, while we found insufficient justification for 40% of such trials. Most trials were successful in proving noninferiority, and when the hazard ratio was pooled across these trials, there was no detrimental effect on OS.

Noninferiority trials in oncology have previously been criticized for "critical deficiencies in design and reporting."^[@zoi190377r33]^ In this cohort, OS was the primary end point in fewer than one-third of noninferiority trials. However, using a noninferiority hypothesis implies a willingness to compromise efficacy outcomes to achieve benefits in other areas. Surrogate measures, such as progression-free survival, have been shown to overestimate (or, in the case of immunotherapy drugs, underestimate^[@zoi190377r34]^) benefit and translate to smaller than expected gains in OS. In most cases these surrogate measures have been shown to lack correlation with OS.^[@zoi190377r35]^ Thus, a trial testing noninferiority in a surrogate measure is ethically challenging if it is impossible to estimate the magnitude of potential compromise in efficacy and communicate that clearly to patients participating in such trials as part of the informed consent process. Investigators should therefore be wary of conducting trials assessing noninferiority on surrogate measures.

The criteria to define noninferiority among the trials in the cohort varied from 1.08 to 1.33 for the upper bound of the CI of the HR for OS, which means from an 8% to a 33% increase in the hazard of death was considered acceptable (noninferior) in these trials. Furthermore, in multiple cases, this upper limit was defined not for a 95% CI but for a 90% or even an 80% CI. As previous studies have shown, there are no set methods for determining limits defining noninferiority.^[@zoi190377r3],[@zoi190377r33]^ We also found none of the 4 key justifications---lower toxic effects, lower cost, ease of administration, or better quality of life---for using noninferiority designs in approximately 40% of the cohort. Such benefits should be the primary rationale for a patient consenting to participate in a trial testing if a new treatment is not worse than the standard treatment by a prespecified margin.

Our final objective was to assess if patients enrolled in the experimental arm of noninferiority trials experienced reduced OS compared with those in the control arms. Reassuringly, we found no such association. However, this pooled result should be interpreted with caution because, when examining individual trials, we found 10 trials (43%) in which the HR was more than 1, including 1 in which the HR was significantly more than 1. Similarly, 1 noninferiority trial actually proved superiority for the experimental arm. Subgroup analyses revealed no differences in OS based on funding or reporting 1 of the 4 key justifications for noninferiority.

Half of the trials in our study had industry funding, and having industry funding was significantly associated with missing the justifications we identified for the noninferiority design. Industry-funded noninferiority trials also were successful in proving noninferiority in 83% of cases, although the association of success with funding was not significant. Our results are similar to those of a previous analysis^[@zoi190377r4]^ showing that 43% of noninferiority trials in oncology were industry funded, 73% reported positive results, and OS was the primary end point in 25%. Another study^[@zoi190377r36]^ that included all noninferiority trials across disciplines showed that 83% produced favorable results irrespective of funding source, similar to our findings. These results should be interpreted in light of the fact that success in achieving noninferiority depends not only on the intervention but also on the criteria used to define noninferiority, which is often arbitrary. Furthermore, we cannot rule out publication bias against noninferiority trials that failed to achieve noninferiority.

These findings are important for those helping design and oversee the conduct of noninferiority trials in oncology. Noninferiority trials may be attractive because of the high probability of success.^[@zoi190377r8]^ Indeed, the noninferiority design has been described as having a low risk of failure.^[@zoi190377r36]^ However, our data show that institutional review boards and drug regulators should take an active role in adjudicating whether the noninferiority design is acceptable for the given question. When noninferiority design trials are considered important, the criteria to define noninferiority should be clearly defined based on a widely accepted rationale and should incorporate patient input.

The Consolidated Standards of Reporting Trials (CONSORT) statement on reporting noninferiority trials recommends providing a rationale for the noninferiority design and the criteria for defining noninferiority^[@zoi190377r37]^; however, further research is needed to assess if this recommendation has improved reporting practices in oncology. Similarly, the US Food and Drug Administration has issued a guidance for industry on noninferiority trials. However, the US Food and Drug Administration recommends a noninferiority design be chosen "when it would not be ethical to use a placebo."^[@zoi190377r38]^ While that is necessary, it is not sufficient, and superiority design trials against an active comparator should be encouraged unless the noninferiority design is justified for other compelling reasons, such as the ones we have mentioned. The guidance could also be improved by highlighting the need to incorporate patient input on the acceptable margin for defining noninferiority among various tumor types.

Limitations {#H2-7-ZOI190377}
-----------

This study has limitations. Although our analysis included trials involving more than 21 000 participants, for the analysis of the association of different parameters with funding, this study was limited by the relatively small total number of trials (23). Another important limitation is our consensus-based definition for adjudicating whether the noninferiority design was justified. However, other authors have also concluded that "any new treatment, even if noninferior to standard treatment, should have some benefits, such as for quality of life, cost, or safety."^[@zoi190377r11]^ We focused on noninferiority trials testing OS end points; however, many trials also test noninferiority in surrogate measures, such as response rates. The association of such trials with patient treatment outcomes is a topic for future research.

Conclusions {#H1-5-ZOI190377}
===========

Noninferiority randomized trials in oncology should be used only when there are important potential benefits that the experimental drug can offer patients. However, among 23 such trials testing OS, we found that a substantial fraction did not offer any of the 4 key criteria for justification. Greater attention to the use of noninferiority designs in cancer drug clinical trials from local and national regulators is warranted.
